Markets Collapse As Vaccine Subject Gets Ill

By Staff of Admiral Markets

Wednesday, September 9, 2020 8:09 AM EDT

AstraZeneca (AZN) - a leader in the race to find a coronavirus vaccine - stopped its trial after one of the test subject's fell ill in a potential adverse reaction to the company's experimental COVID-19 vaccine. The delay in this trial is likely to derail the speed of immunization around the world causing concern for many traders and investors.

Markets collapse as vaccine subject gets ill

On the back of the news, global stock markets sank along with oil and commodity currencies. Investors fled to safe-haven currencies such as the Swiss Franc and the Japanese Yen.

The experimental vaccine is being developed by AstraZeneca and researchers from the University of Oxford. It had been one of the leading candidates to reach the global market. The company is now undergoing a standard review to try and understand the unexplained illness.

While shares in AstraZeneca dropped sharply on the news, shares in other rivals traded higher. While US President Donald Trump has stated a vaccine will be available by the end of the year, investors are concerned about the rising pace of infections around the world bringing the possibility of a second wave closer.

Disclaimer: The given data provides additional information regarding all analysis, estimates, prognosis, forecasts or other similar assessments or information (hereinafter "Analysis") ...

Disclaimer: The given data provides additional information regarding all analysis, estimates, prognosis, forecasts or other similar assessments or information (hereinafter "Analysis") published on the website of Admiral Markets. Before making any investment decisions please pay close attention to the following:

This is a marketing communication. The content is published for informative purposes only and is in no way to be construed as investment advice or recommendation. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and that it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Any investment decision is made by each client alone whereas Admiral Markets Group AS investment firms (Admiral Markets) shall not be responsible for any loss or damage arising from any such decision, whether or not based on the content.

The Analysis is prepared by an independent analyst (hereinafter "Author") based on the Author's personal estimations.

To ensure that the interests of the clients would be protected and objectivity of the Analysis would not be damaged Admiral Markets has established relevant internal procedures for prevention and management of conflicts of interest.

Whilst every reasonable effort is taken to ensure that all sources of the content are reliable and that all information is presented, as much as possible, in an understandable, timely, precise and complete manner, Admiral Markets does not guarantee the accuracy or completeness of any information contained within the Analysis.

Any kind of past or modeled performance of financial instruments indicated within the content should not be construed as an express or implied promise, guarantee or implication by Admiral Markets for any future performance. The value of the financial instrument may both increase and decrease and the preservation of the asset value is not guaranteed.

Leveraged products (including contracts for difference) are speculative in nature and may result in losses or profit. Before you start trading, you should make sure that you understand all the risks.

less

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.